5.46
+1.87%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hainan Huluwa Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 605199.SS. It has been listed since 10 July 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥900.8m and a net loss of CN¥287.4m. At that date it held total assets of CN¥2.60bn and shareholders' equity of CN¥412.7m.
Hainan Huluwa Pharmaceutical Group Co. Ltd. engages in the research and development, production, and sales of proprietary Chinese medicines and chemical reagent. The company is headquartered in Haikou, Hainan. The company went IPO on 2020-07-10. Its products are used in the pharmaceutical fields of respiratory system, digestive system, systemic anti-infection, including pediatric lung heat cough asthma granules, bromhexine hydrochloride for injection, compound Banlangen granules, Keke tablets, omeprazole enteric-coated capsules , Changyanning (capsules and granules), omeprazole sodium for injection, sodium diisopropylamine dichloroacetate for injection and cefixime dispersible tablets, among others. The firm also provides gynecological medicine, cardiovascular system medicine and neurological system medicine preparation products. The firm operates its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jul 2020
- Employees
- 2,083
- Website
- huluwayaoye.com ↗
Leadership
Pay as last reported
- Ms. Jingping LiuChairman of the Board, since 2016CN¥1.4m
- Ms. Hui YuChief Financial Officer, Deputy General Manager, Director, since 2022
- Ms. Mingrui ZhangGeneral Manager
- Ms. Junling LiDeputy General Manager, Director, since 2019CN¥727,400
- Mr. Chunhong LouDeputy General Manager, Director, since 2016CN¥762,700
- Mr. Peihu LiDeputy General ManagerCN¥359,300
- Mr. Tianbao WeiDeputy General ManagerCN¥288,000
- Mr. Qingtao WangSecretary of the BoardCN¥269,600
- Mr. Junbin HuDirectorCN¥198,600
- Mr. Qibo TangDirector
- Mr. Jike MaIndependent DirectorCN¥100,000
- Mr. Bo WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company engages in research and development of proprietary Chinese medicines.
- It produces chemical reagents and various pharmaceutical preparations.
- The firm operates its businesses in the domestic market.
Weaknesses
- The company is headquartered in Haikou, Hainan.
- It employs 2,083 full-time employees globally.
- The firm went public on July 10, 2020.
Opportunities
- Products are used in the respiratory system field.
- The firm provides gynecological medicine preparations.
- Chemical reagents support various pharmaceutical applications.
Threats
- The source description is treated as untrusted facts.
- Competitors may offer similar proprietary Chinese medicines.
- Regulatory changes could impact domestic market operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.